ProMIS Announces Completion of Continuance
TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 14, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN) (“ProMIS” or the…
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
Company to voluntarily delist from the Toronto Stock Exchange (TSX) Last trading day on TSX will be July 21, 2023…
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
In preclinical studies, PMN310 demonstrated the ability to selectively target and protect against pathogenic Aβ oligomers The IND clearance of…
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
ProMIS Neurosciences Inc. Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstrated selective binding and protection against toxic amyloid-beta oligomers Preclinical…
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration Preclinical data that…